Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

134.53 -1.73 (-1.27%)
Official Closing Price Updated: 7:00 PM EDT, Sep 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,811,599
Open 134.04
Bid (Size) 132.97 (1)
Ask (Size) 134.55 (1)
Prev. Close 136.26
Today's Range 133.63 - 134.91
52wk Range 86.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.31%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow... 
Via Benzinga
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
The companies are well-known for their obesity treatments and could reach a $1 trillion market cap before carmaker Tesla. 
Via Investor's Business Daily

Performance

YTD
+31.75%
+31.75%
1 Month
+6.77%
+6.77%
3 Month
-4.59%
-4.59%
6 Month
+7.84%
+7.84%
1 Year
+41.53%
+41.53%

More News

Read More
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
Via Benzinga
Looking At Novo Nordisk's Recent Unusual Options Activity
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
Via Benzinga
Exposures Product Safety
Market Thoughts This Labor Day Weekend
Via Talk Markets
Topics Economy
Exposures Interest Rates
Ozempic: Unexpected Anti-Aging Miracle Drug? Researchers Reveal Surprising Potential
Via Benzinga
3 No-Brainer Stocks to Buy in September
Via The Motley Fool
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
Via The Motley Fool
Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
Via Benzinga
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
Via The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Is Eli Lilly Stock a No-Brainer Buy After the Company's Brilliant Zepbound Move?
Via The Motley Fool
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
Via Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
Via Investor's Business Daily
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
Via The Motley Fool
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
Via Benzinga
Eli Lilly’s Path to the Next Trillion Market Capitalization
Via MarketBeat
Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices
Via Benzinga
This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money
Via The Motley Fool
2 No-Brainer Healthcare Stocks to Buy With $1,000
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.